Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application

NCT05104099 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.

NCT NCT05104099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application
Lead sponsor
Institut de Cancérologie de Lorraine
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2021
Completion date
May 25, 2025
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated vulvar intraepithelial neoplasia, vulvar high grade squamous intraepithelial lesion, vulvar intraepithelial neoplasia